Results 71 to 80 of about 18,957 (200)

Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease

Advanced Science, Volume 13, Issue 20, 9 April 2026.
This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia, Rebecca Parodi‐Rullan, Rafael Vazquez‐Torres, Ashley Carey, Huaqing Zhao, Sabzali Javadov, Silvia Fossati   +6 more
wiley   +1 more source

Interactions of memantine and rivastigmine with graphene oxide nanocarrier and beta-amyloid protein using molecular docking and in-silico methods

Heliyon
Alzheimer's disease is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles. Effective therapeutic strategies involve inhibiting the formation of beta-amyloid aggregates and destabilizing existing ones.
Fateme Davoudi, Nasrin Shadjou, Mahdieh Darroudi   +2 more
doaj   +1 more source

Synthesis of p‐Coumarates With Potential Anti‐Alzheimer's Action: Enzyme Inhibition and In Silico Studies

Chemistry &Biodiversity, Volume 23, Issue 4, April 2026.
ABSTRACT Alzheimer's disease (AD) is a fatal neurodegenerative disorder that affects cognition, memory, and behavior. Such a disease is considered the most common cause of dementia and affects a large portion of the elderly population worldwide. Currently, cholinesterase inhibitors are used to reduce the symptoms and rate of progression of this disease.
Susiany Pereira Lopes, Jeremias Justo Emídio, Allana Brunna Sucupira Duarte, Ilkay Erdogan Orhan, Fatma Sezer Senol Deniz, Ramin Ekhteiari Salmas, Damião Pergentino de Sousa   +6 more
wiley   +1 more source

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice

Patient Preference and Adherence, 2013
Secundino López-Pousa,1 Francisco Javier Arranz21Unit for Assessment of Memory and Dementia, Institut d’Assistència Sanitària de Girona, Salt, Girona, 2CNS Area, Medical Department and Health Innovation, Esteve,
López-Pousa S, Arranz FJ
doaj  

Sparassis crispa and a Bioactive Compound Therein, Ergosterol, Were Effective in Preventing Acetylcholinesterase Inhibition In Vitro and In Vivo

Food Science &Nutrition, Volume 14, Issue 4, April 2026.
Sparassis crispa extract exhibited acetylcholinesterase inhibitory and antioxidant activities, and ergosterol was identified as a major bioactive sterol. In a TMT‐induced mouse model, both the extract and ergosterol improved spatial working memory and learning retention while reducing brain AChE activity and lipid peroxidation.
Chan Kyu Park, Gyumin Kang, Soo Jung Choi, Yoon Seo Lee, Eui‐Cheol Shin, Hyo In Kim, Jinbong Park, Nam Su Oh, Hyung Taek Cho, Tae Gyun Kim, Jeong Hoon Pan, Dong‐Hoon Shin, Young‐Jun Kim, Jae Kyeom Kim   +13 more
wiley   +1 more source

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Dementia and Geriatric Cognitive Disorders Extra, 2011
Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and ...
Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Ana Graf, Toru Shirahase, Hyosung Kim, Akifumi Fujii, Joji Mori, Akira Homma   +8 more
doaj   +1 more source

Alzheimer's Disease in Africa: A Scoping Review Protocol

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims The global burden of Alzheimer's disease (AD) is set to increase in the next three decades particularly because of the global increase in life expectancy. The state of AD in Africa is a cause for concern because the continent's rapid population growth and demographic transition will be major contributors to AD's increased ...
Jonathan Ayeyi Nuamah, Fortune Kekeli Avorgbedor, Shirley Sarah Dadson, Ernest Adu Asamoah, Princess Yaa Benson, Kennedy Kwami Edem Kukuia, Ulrick Sidney Kanmounye   +6 more
wiley   +1 more source

Quality of life evidence for patients with Alzheimer’s disease: use of existing quality of life evidence from the ADENA trials to estimate the utility impact of Exelon® [PDF]

This paper utilises the Mini-Mental State Examination (MMSE) score of patients with Alzheimer’s disease to establish a relationship between disease progression and quality of life measures, and the author also compares his results to findings from the ...
Brazier, J
core   +1 more source

Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer’s Disease: Analyses with Concomitant Memantine Usage as a Factor [PDF]

, 2015
Background: ACTION, a 24-week, prospective, randomized, parallel-group, double-blind study in patients with severe Alzheimer’s disease (AD), demonstrated significant efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on the Severe Impairment ...
Farlow, Martin R., Grossberg, George T., Meng, Xiangyi, Velting, Drew M.   +3 more
core   +1 more source

The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na+, K+)-, Mg2+-ATPase activities, antioxidant status, and learning performance of aged rats

Neuropsychiatric Disease and Treatment, 2008
Haris Carageorgiou1, Antonios C Sideris1, Ioanna Messari1, Chrissoula I Liakou1, Stylianos Tsakiris21Department of Pharmacology, 2Department of Physiology, Medical School, University of Athens, Athens, GreeceAbstract: We investigated the effects of ...
Haris Carageorgiou, Antonios C Sideris, Ioanna Messari, Chrissoula I Liakou, Stylianos Tsakiris   +4 more
doaj